dr anslyn

Dr. Eric Anslyn

Dr. Eric Anslyn

Dr. Eric Anslyn is University Distinguished Teaching Professor and Welch Regents Chair in the Department of Chemistry at The University of Texas at Austin. In 2018, Anslyn was selected by the Howard Hughes Medical Institute to be an HHMI professor. Prior to joining the University of Texas, Anslyn completed postdoctoral work at Columbia University in New York. He has authored more than 300 scientific articles and filed more than 50 patents. Anslyn is a cofounder of Erisyon, Inc.

Academic Appointment(s)

  • University Distinguished Teaching Professor and Welch Regents Chair, Department of Chemistry, The University of Texas at Austin

Educational Background

  • California State University, Northridge: B.S. Chemistry (1982)
  • California Institute of Technology: Ph.D., Chemistry (1987)
  • Columbia University: Postdoctoral Fellow, Chemistry (1987 – 1989)

Recent Publications

  • “Synthesis of Carboxy ATTO 647N Using Redox Cycling for Xanthone Access” Bachman, J.L.; Pavlich, C.I.; Boley, A.J.; Marcotte, E.M.; Anslyn, E.V. Org. Lett. 2020, 22, 381-385.
  • “Regineering a Reversible Covalent-Bonding Assembly to Optically Detect ee in b-Chiral Primary Alcohols” Matthew, M.; Featherson, A.L.; Choi, S.; King, S.; Miller, S.J.; Anslyn, E.V. Chem, 2019, 5, 3196-3206.
  • “2-Amino-3’-dialkylaminobiphenyl-base fluorescent intracellular probes for nitric oxide surrogate N 2 O 3 ” Escamilla, P.R.; Shen, Y.; Zhang, Q.; Hernandez, D.S.; Howard, C.J.; Qian, X.; Filonov, D.Y.; Kinev, A.V.; Shear, J.B.; Anslyn, E.V.; Yang, Y. Chem. Sci. 2019, in press.
  • “Quantification of ERK kinase activity in biological sampels using differential sensing” Zamora-Olivares, D,; Kaoud, T.; Zeng, L.; Pridgen, J.R.; Zhuang, D.; Ekpo, Y.E.; Nye, J.R.; Telles, M.; Anslyn, E.V.; Dalby, K. ACS Chem Biol 2019, In press
  • “Modulating multi-functional ERK complexes by covalent targeting of a recruitiment site in vivo” Kaoud, T.S.; Johnson, W.H.; Ebelt, N.D.; Pieserchio, A.; Zamora-Olivares, D.; Van Ravenstein, S.X.; Pridgen, J.R.; Edupuganti, R.; Sammons, R.; Cano, M.; Anslyn, E.V.; Dalby, K. Nat. Comm. 2019, 10, 1-15.
  • “Expanding the limits of the second genetic code with ribozymes” Lee, J.; Schwieter, K.E.; Watkins, A.M.; Kim, D.S.; Yu, H.; Schwarz, K.J.; Lim, H.; Coronado, J.; Byrom, M.; Anslyn, E.V.; Ellington, A.D.; Moore, J.; Jewett, M. Nat. Comm. 2019, 10, 1-12.
  • “Design of Chiral Supramolecular Polymers Exhibiting a Negative Nonlinear Response” Chen, X.X.; Lin, X.- Y.; Wu, X.; Gale, P.A.; Anslyn, E.V.; Jiang, Y.-B. J. Org. Chem. 2019, 84, 14587-14592.
  • “Mechanistic studies of a “Declick” reaction” Meadows, M.K.; Sun, X.; Kolesnichenko, I.V.; Hinson, C.M.; Johnson, K.A. Chem. Sci. 2019, 10, 8817-8824.
  • “The Mechanisms of Boronate Ester Formation and Fluorescent Turn-On in Ortho-aminomethylphenylboronic Acids” Sun X; Chapin BM; Metola P; Collins B; Wang B; James TD; Anslyn EV, Nat. Chem. 2019, 11(9), 768-778, DOI: doi: 10.1038/s41557-019-0314-x.
  • “Rapid Optical Determination of Enantiomeric Excess, Diastereomeric Excess, and Total Concentration Using Dynamic-Covalent Assemblies: A Demonstration Using 2-Aminocyclohexanol and Chemometrics” Herrera BT; Moor SR; McVeigh M; Roesner EK; Marini F; Anslyn EV, J. Am. Chem. Soc., 2019, 141(28), 11151-11160, DOI: 10.1021/jacs.9b03844

News


novosteo

Fracture targeting therapeutic for bone healing
PI: Dr. Philip Low, Purdue University
Visit site


morphimmune

Hyper-targeted small molecules for reprogramming immune cells to treat disease
PI: Dr. Philip Low, Purdue University
Visit site


erisyon

Single molecule protein sequencing
PI: Dr. Edward Marcotte, University of Texas at Austin
Visit site


eradivir

Targeted therapeutics platform for Infectious diseases
PI: Dr. Philip Low, Purdue University


asalyxa logo

AsalyxaBio

ASX-100 neutrophil targeting platform to treat significant unmet medical needs
PI: Dr. Lola Eniola-Adefeso, University of Michigan
Visit site


Dr. Edward Marcotte

Dr. Edward Marcotte

Dr. Edward Marcotte

Dr. Edward Marcotte is the Mr. and Mrs. Corbin J. Robertson, Sr. Regents Chair in Molecular Biology at the University of Texas at Austin, where he also serves as Co-Director of the Center for Systems and Synthetic Biology. Dr. Marcotte has spent more than 20 years researching proteomics, synthetic biology and bioinformatics and has authored more than 200 articles and filed 16 patents on his work. He is the co-founder of Erisyon, Inc.

Academic Appointment(s)

  • Professor, Molecular Biosciences, College of Natural Sciences, University of Texas at Austin
  • Mr. and Mrs. Corbin J. Robertson, Sr. Regents Chair in Molecular Biology, University of Texas at Austin

Educational Background

  • University of Texas at Austin: B.S. (National Merit Scholar), Microbiology (1990)
  • University of Texas – Austin: Ph.D. (NSF Predoctoral Fellow), Biochemistry (1995)
  • University of California, Los Angeles: Hollaender Distinguished Postdoctoral Fellow (2000)

Recent Publications

  • Floyd BM, Drew K, Marcotte EM, Systematic Identification of Protein Phosphorylation-Mediated Interactions, bioRxiv, Posted September 19: (2020)
  • Drew K, Wallingford JB, Marcotte EM, hu.MAP 2.0: Integration of over 15,000 proteomic experiments builds a global compendium of human multiprotein assemblies, bioRxiv, Posted September 16: (2020)
  • Garge RK, Cha HJ, Lee, C, Gollihar JD, Kachroo AH, Wallingford JB, Marcotte EM, Antifungal benzimidazoles disrupt vasculature by targeting one of nine β-tubulins, bioRxiv, Posted September 15: (2020)
  • Devitt C, Lee C, Cox R, Papoulas O, Alvarado J, Marcotte EM, Wallingford JB, Twinfilin1 controls lamellipodial protrusive activity and actin turnover during vertebrate gastrulation, bioRxiv, Posted September 3: (2020)
  • Boulgakov AA, Moor SR, Jo HH, Metola P, Joyce LA, Marcotte EM, Welch CJ, Anslyn EV, Next-Generation TLC: A Quantitative Platform for Parallel Spotting and Imaging, J Org Chem, 85(15):9447–9453 (2020)
  • Garge RK, Laurent JM, Kachroo AH, Marcotte EM, Systematic humanization of the yeast cytoskeleton discerns functionally replaceable from divergent human genes, Genetics, 215(4):1153-1169 (2020)
  • Laurent J, Garge RK, Teufel AI, Wilke CO, Kachroo AH, Marcotte EM, Humanization of yeast genes with multiple human orthologs reveals principles of functional divergence between paralogs, PLoS Biology, 18(5):e3000627 (2020)
  • Lee C, Cox RM, Papoulas O, Horani A, Drew K, Devitt CC, Brody SL, Marcotte EM, Wallingford JB, Functional partitioning of a liquid-like organelle during assembly of axonemal dyneins, bioRxiv, Posted April 21: (2020)
  • McWhite CD, Papoulas O, Drew K, Cox RM, June V, Dong OX, Kwon T, Wan C, Salmi ML, Roux, SJ Jr., Browning KS, Chen ZJ, Ronald PC, Marcotte EM, A pan-plant protein complex map reveals deep conservation and novel assemblies, Cell, 181(2):460-474.e14 (2020)
  • McCafferty C, Verbeke EJ, Marcotte EM, Taylor DW, Structural Biology in the Multi-Omics Era, Journal of Chemical Information and Modeling, 60(5):2424-2429 (2020)

News


Dr. Lola Eniola Adefeso

Dr. Lola Eniola-Adefeso

Dr. Lola Eniola-Adefeso

Dr. Omolola (Lola) Eniola-Adefeso is the University Diversity and Social Transformation Professor in the Department of Chemical Engineering at the University of Michigan Ann Arbor. She also holds joint appointments in Biomedical Engineering and Macromolecular Science & Engineering and serves on the steering committee of the UM Biointerfaces Institute. She holds a PhD from the University of Pennsylvania and served two years as a NIH Postdoctoral Fellow at the Baylor College of Medicine before coming to Michigan. Dr. Eniola-Adefeso is a co-founder of Asalyxa Bio.

Academic Appointment(s)

  • Professor, Department of Chemical Engineering, Department of Biomedical Engineering, Macromolecular Science and Engineering, University of Michigan Ann Arbor

Educational Background

  • University of Maryland Baltimore County: B.S. Chemical Engineering (1999)
  • University of Pennsylvania: M.S.E. Chemical Engineering (2000)
  • University of Pennsylvania: Ph.D. Chemical and Biomolecular Engineering (2004)
  • Baylor College of Medicine: Post-doctoral work, Immunology, Leukocyte Biology (2004-2006)

Recent Publications

  • Safari, H., Kelley, W., and O. Eniola-Adefeso. (2020) “Neutrophils preferentially eat elongated particles – opportunity for selective targeting in acute inflammatory diseases.” Science Advances. 6 (24), eaba147
  • Czaja, B., M. Gutierrez, G. Zavodszky, D. de Kanter, A. Hoeskstra, O. Eniola-Adefeso. (2020) “The influence of red blood cell deformability on hematocrit profiles and platelet margination.” PLOS Computational Biology. 16(3):e1007716
  • Safari, H., Lee, JKH, and O. Eniola-Adefeso. (2020) “Effect of shape, rigidity, size and flow on targeting” in Nanoparticles for Biomedical Applications, 55-66.
  • Sule, G.; W. Kelley; S. Yalavarthi; A. Vreede; A. Banka; P. Bockenstedt; O. Eniola-Adefeso; J. Knight. (2020) “Increased adhesive potential of antiphospholipid syndrome neutrophils mediated by beta-2 integrin Mac-1.” Arthritis & Rheumatology. 72(1):114-124.
  • Kelley, W.J., P.J. Onyskiw, C.A. Fromen, and O. Eniola-Adefeso. (2019) “Model particulate drug carriers modulate leukocyte adhesion in human blood flows.” ACS Biomaterials Science Engineering. 5(12): 6530-6540
  • Kelley, W.J., C.A. Fromen and O. Eniola-Adefeso. (2018) “Enhance update of PEGylated particles by human neutrophils.” Acta Biomaterialia. 79: 283-293
  • Gutierrez, M., Ojeda, L.S.* and O. Eniola-Adefeso. (2018) “Vascular-Targeted Carrier Margination Efficacy in the Presence of Rigid Red Cells: Implications for Disease.”  Biomicrofluidics. 12(4): 042217.
  • Gutierrez, M., Fish, M.B., Golinski, A.W.* and O. Eniola-Adefeso. (2018) “Presence of Rigid Red Cells in Blood Flow Interferes with the Vascular Wall Adhesion of Leukocytes.” Langmuir. 34 (6): 2363-2372.
  • Safari, H. and O. Eniola-Adefeso. (2018) “Modified two-step emulsion solvent evaporation technique for fabricating biodegradable submicron rod-shaped particles.” Journal of Colloid and Interface Science. 518: 174-183.
  • Boas-Favero, C.V., Moran, S.E. and O. Eniola-Adefeso. (2018) “The power of peer mentoring in enabling a diverse and inclusive environment in a chemical engineering graduate program.” Chemical Engineering Education. 52(2):79-88.

News


Dr. Philip S. Low

Professor Philip S. Low

Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University.  Dr. Low has spent more than 45 years doing pioneering work in the fields of tissue regeneration, infectious diseases, erythrocyte membranes and auto-immune diseases.  He has published more than 500 articles and has 500 patents/patents pending. Dr. Low is the co-founder of three RBP portfolio companies: Novosteo, Eradivir, and MorphImmune.

Academic Appointment(s)

  • Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, Purdue University

Educational Background

  • Brigham Young University, B.S. Chemistry, 1971
  • University of California San Diego, Ph.D. Biochemistry, 1975

Recent Publications

  • Standardization and optimization of intraoperative molecular imaging for identifying primary pulmonary adenocarcinomas. Predina, J.D., Okusanya, O., Newton, A.D., Low, PS and Singhal, S. Molecular Imaging and Biology. 20(1), pp.131-138 (2018)
  • Imaging and Methotrexate Response Monitoring of Systemic Inflammation in Arthritic Rats Employing the Macrophage PET Tracer [18F]Fluoro-PEG-Folate. Chandrupatla DMSH, Jansen G, Mantel E, Low PS, Matsuyama T, Musters RP, Windhorst AD, Lammertsma AA, Molthoff CFM, van der Laken CJ1. Contrast Media Mol Imaging 10:1155 (2018)
  • Fluorescence-guided surgery of cancer: applications, tools and perspectives. Low PS, Singhal S, Srinivasarao M. Curr Opin Chem Biol. 45:64-72 (2018)
  • An open label trial of folate receptor-targeted intraoperative molecular imaging to localize pulmonary squamous cell carcinomas. Predina JD, Newton AD, Xia L, Corbett C, Connolly C, Shin M, Sulyok LF, Litzky L, Deshpande C, Nie S, Kularatne SA, Low PS, Singhal S. Oncotarget. 9:13517-13529 (2018)
  • Synthesis and Evaluation of a Novel 64Cu- and 67Ga-Labeled Neurokinin 1 Receptor Antagonist for in Vivo Targeting of NK1R-Positive Tumor Xenografts. Zhang H, Kanduluru AK, Desai P, Ahad A, Carlin S, Tandon N, Weber WA, Low PS. Bioconjug Chem. 10.1021 (2018)
  • New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange. Rangasamy L, Chelvam V, Kanduluru AK, Srinivasarao M, Bandara NA, You F, Orellana EA, Kasinski AL, Low PS. Bioconjug Chem. 10.1021 (2018)
  • Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Shen J, Hu Y, Putt KS, Singhal S, Han H, Visscher DW, Murphy LM, Low PS. Oncotarget. 9:4485-4495 (2017)
  • Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. Boogerd LSF, Hoogstins CES, Gaarenstroom KN, de Kroon CD, Beltman JJ, Bosse T, Stelloo E, Vuyk J, Low PS, Burggraaf J, Vahrmeijer AL. Oncotarget. 9: 791-801 (2017)
  • Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases. Poh S, Chelvam V, Ayala-López W, Putt KS, Low PS. Nanomedicine. 14:1033-1043 (2018)
  • A Phase I Clinical Trial of Targeted Intraoperative Molecular Imaging for Pulmonary Adenocarcinomas. Predina JD, Newton AD, Keating J, Dunbar A, Connolly C, Baldassari M, Mizelle J, Xia L, Deshpande C, Kucharczuk J, Low PS, Singhal S. Ann Thorac Surg. 105:901-908 (2018)

News